SCHEMBL31457054

SCHEMBL31457054

Cn1cc(-c2cc(F)cc(CNC(=O)c3ncnc4nc([C@@H]5CCCN5C(=O)OCc5ccccc5)[nH]c34)c2)cn1

nearest known ligand 0.40

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ MET P08581 2/20 0.40
▸ MERTK Q12866 10/20 0.38
▸ AXL P30530 8/20 0.38
▸ TYRO3 Q06418 1/20 0.37
▸ GRIN2B Q13224 1/20 0.36
▸ PRCP P42785 2/20 0.35
▸ WNT1 P04628 1/20 0.35
▸ DYRK1A Q13627 1/20 0.35
▸ AADAT Q8N5Z0 1/20 0.35
▸ CLK1 P49759 1/20 0.35
▸ CPT2 P23786 1/20 0.35
▸ CPT1A P50416 1/20 0.35
▸ KIT P10721 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30751331 1.00 MET (0.40) METMERTKAXLTYRO3GRIN2B
SCHEMBL30751262 1.00 MET (0.40) METMERTKAXLTYRO3GRIN2B
SCHEMBL31457006 1.00 MET (0.40) METMERTKAXLTYRO3GRIN2B
SCHEMBL30751096 0.89 GRIN2B (0.43) METMERTKAXLTYRO3GRIN2B
SCHEMBL31457001 0.89 GRIN2B (0.43) METMERTKAXLTYRO3GRIN2B
SCHEMBL27376355 0.89 GRIN2B (0.41) METMERTKAXLTYRO3GRIN2B
SCHEMBL30751111 0.89 GRIN2B (0.41) METMERTKAXLTYRO3GRIN2B
SCHEMBL31456948 0.89 GRIN2B (0.41) METMERTKAXLTYRO3GRIN2B
SCHEMBL31457053 0.87 GRIN2B (0.41) GRIN2BPRCPAADATCPT2CPT1A
SCHEMBL30751273 0.87 GRIN2B (0.41) GRIN2BPRCPAADATCPT2CPT1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119654324-A Novel compounds as hypoxia inducible factor 1 (HIF-1) inhibitors or Vascular Endothelial Growth Factor (VEGF) inhibitors and pharmaceutical compositions comprising the same 株式会社次代生物科学 2025-03-18 — — CN disclosed
Send feedback